BIOM30001 Lecture Notes - Lecture 32: Venlafaxine, Baclofen, Tetrahydrocannabinol
Document Summary
Drug produced-->characterised-->reduces nicotine induced dopamine release and self. Drug produced-->characterised-->reduces nicotine induced dopamine release and self administration of dopamine-->passed for toxicity and clinical trials-->but worsens schizophrenia - been linked to precipitation of manic episodes & worsening of schizophrenic symptoms. Active immunization - nicotine conjugated via a succinic acid linker to recombinant. Gabapentin - ca channel blocker / gabab agonist. Aripiprazole atypical antipsychotic (d2 partial agonist) (recruiting for ct): in clinical trials. Vigabatrin gaba transaminase inhibitor (recruiting for ct (clinical trial)) N-acetylcysteine (restores glt1 function) (recruiting for ct): for cocaine, opiates and nicotine in animals. Dysfunction of glutamate homeostasis in cortical striatal circuitry restored by restoring glt1 (glutamate transporter) by upregulating it. Laam (l-alpha-acetylmethadol) discontinued due to rare adverse cardiac events. Inhibits noradrenaline release by activating an inhibitory autoreceptor, which reduces corticol noradrenaline release. Memantine / naltrexone (recruiting for ct): partial mnda antagonist. 24% of laam vs 12% mm abstinent for >12 weeks.
